Project: Covalently linked-ADC as a new and innovative technology for cancer therapy

The enzymatic covalently conjugated drugs, CovIsoLink allows the coupling of 2 drug molecules on a specific site of 1 monoclonal antibody. We aim to validate the proof of concept of our new & patented technology compared to the existing T-DM1 ADC for breast cancer developed by chemical conjugation. The new CovHer2-ADC will be studied in vitro & in vivo using T-DM1 ADC as a reference. The results expected are homogenous ADC preparations rather than mixtures resulting in greater efficacy & safety.

Acronym CovIsoLink (Reference Number: 10478)
Duration 01/09/2016 - 01/09/2018
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 5

Project partner

Number Name Role Country
24208 COVALAB Coordinator France
24209 IONTAS Ltd Partner United Kingdom
24210 Université Claude Bernard Lyon 1 Partner France